Resistance to the bNAbs 10-1074 and 3BNC117 may significantly impact clinical outcome
following their therapeutic administration. Predicting bNAb resistance may help to lower the …

Antibodies that target the gp120-gp41 interface of the HIV-1 envelope (Env) trimer comprise
a commonly elicited category of broadly neutralizing antibodies (bNAbs). Here, we isolate …

Guiding HIV-1 vaccine development with preclinical nonhuman... : Current Opinion in HIV and
AIDS Guiding HIV-1 vaccine development with preclinical nonhuman primate research : Current …

The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at
inducing neutralizing antibodies (NAbs) against HIV-1. The clinical candidate immunogen …

Peptide therapeutics have recently gained momentum in antiviral therapy due to their
increased potency and cost-effectiveness. Interaction of the HIV-1 envelope gp120 with the …

For use in prevention and treatment, HIV-1 broadly neutralizing antibodies (bnAbs) have to
overcome Env conformational heterogeneity of viral quasispecies and neutralize with …

Broadly neutralizing antibodies (bNAbs) for HIV-1 prevention or cure strategies must inhibit
transmitted/founder and reservoir viruses. Establishing sensitivity of circulating viruses to …

Broadly neutralizing antibodies (bnAbs) targeting the human immunodeficiency virus-1 (HIV-
1) have played a crucial role in elucidating and characterizing neutralization-sensitive sites …

The envelope (Env) glycoproteins on HIV-1 virions are the sole target of broadly neutralizing
antibodies (bNAbs) and the focus of vaccines. However, many cross-reactive conserved …

Broadly neutralizing antibodies against HIV-1 are rare with the 2F5 antibody being one of
the most protective. Insertion of an antibody epitope into a stable and small protein scaffold …